HK1211937A1 - New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors (cyp11b2 cyp11b1)-2- - Google Patents
New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors (cyp11b2 cyp11b1)-2-Info
- Publication number
- HK1211937A1 HK1211937A1 HK15112854.3A HK15112854A HK1211937A1 HK 1211937 A1 HK1211937 A1 HK 1211937A1 HK 15112854 A HK15112854 A HK 15112854A HK 1211937 A1 HK1211937 A1 HK 1211937A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cyp1
- inhibitors
- derivatives
- aldosterone synthase
- cyp11b2 cyp11b1
- Prior art date
Links
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 title 2
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 title 2
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 title 1
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013072348 | 2013-03-08 | ||
| PCT/EP2014/054210 WO2014135561A1 (en) | 2013-03-08 | 2014-03-05 | New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1211937A1 true HK1211937A1 (en) | 2016-06-03 |
Family
ID=50193531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15112854.3A HK1211937A1 (en) | 2013-03-08 | 2015-12-30 | New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors (cyp11b2 cyp11b1)-2- |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9458135B2 (xx) |
| EP (1) | EP2964628B1 (xx) |
| JP (1) | JP6574705B2 (xx) |
| BR (1) | BR112015020834A2 (xx) |
| CA (1) | CA2897417A1 (xx) |
| HK (1) | HK1211937A1 (xx) |
| MX (1) | MX2015010611A (xx) |
| RU (1) | RU2015137972A (xx) |
| WO (1) | WO2014135561A1 (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6117948B2 (ja) * | 2013-03-14 | 2017-04-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルドステロン合成酵素阻害薬としての使用のためのジヒドロキノリン−２−オン誘導体 |
| CN106795138B (zh) * | 2014-10-31 | 2020-04-14 | 豪夫迈·罗氏有限公司 | 新型二氢喹啉吡唑基化合物 |
| CN106604917B (zh) | 2014-10-31 | 2020-10-09 | 豪夫迈·罗氏有限公司 | 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物 |
| EP3212631B1 (en) | 2014-10-31 | 2020-02-12 | F.Hoffmann-La Roche Ag | Pyrazolyl-3,4-dihydroquinolin-2-one aldosterone synthase inhibitors |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| WO2016164476A2 (en) | 2015-04-06 | 2016-10-13 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4710507A (en) * | 1983-12-22 | 1987-12-01 | Pfizer Inc. | Quinolone inotropic agents |
| EP2121652A1 (en) * | 2006-12-18 | 2009-11-25 | Novartis AG | 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| CA2832996C (en) * | 2011-04-26 | 2019-05-07 | Merck Sharp & Dohme Corp. | Tricyclic triazole compounds and their use as aldosterone synthase inhibitors |
| MY169043A (en) * | 2011-09-15 | 2019-02-07 | Hoffmann La Roche | New dihydroquinoline-2-one derivatives |
-
2014
- 2014-03-05 EP EP14707808.3A patent/EP2964628B1/en active Active
- 2014-03-05 JP JP2015560670A patent/JP6574705B2/ja active Active
- 2014-03-05 RU RU2015137972A patent/RU2015137972A/ru not_active Application Discontinuation
- 2014-03-05 CA CA2897417A patent/CA2897417A1/en not_active Abandoned
- 2014-03-05 MX MX2015010611A patent/MX2015010611A/es unknown
- 2014-03-05 WO PCT/EP2014/054210 patent/WO2014135561A1/en active Application Filing
- 2014-03-05 BR BR112015020834A patent/BR112015020834A2/pt active Search and Examination
-
2015
- 2015-09-10 US US14/850,729 patent/US9458135B2/en active Active
- 2015-12-30 HK HK15112854.3A patent/HK1211937A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20160002207A1 (en) | 2016-01-07 |
| EP2964628B1 (en) | 2019-09-11 |
| JP2016510055A (ja) | 2016-04-04 |
| CA2897417A1 (en) | 2014-09-12 |
| BR112015020834A2 (pt) | 2017-07-18 |
| MX2015010611A (es) | 2015-12-16 |
| US9458135B2 (en) | 2016-10-04 |
| EP2964628A1 (en) | 2016-01-13 |
| RU2015137972A (ru) | 2017-04-13 |
| WO2014135561A1 (en) | 2014-09-12 |
| JP6574705B2 (ja) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222387A1 (zh) | 作為 抑制劑的芳基吡咯並吡啶衍生的化合物 | |
| EP2970218B8 (en) | Dna-pk inhibitors | |
| EP3035800A4 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| ZA201406078B (en) | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors | |
| HK1211027A1 (en) | Pyrrolotriazinone derivatives as pi3k inhibitors pi3k | |
| EP3008051A4 (en) | Metalloenzyme inhibitor compounds | |
| ME02576B (me) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| HK1211937A1 (en) | New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors (cyp11b2 cyp11b1)-2- | |
| EP3066219A4 (en) | Compounds and methods for detecting oligonucleotides | |
| EP2870140B8 (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| EP3068389A4 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| HK1212331A1 (en) | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors parp-1 4-- | |
| HK1213484A1 (zh) | 刺激神經發生的異喹啉衍生物 | |
| HK1258911A1 (zh) | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 | |
| HK1210036A1 (en) | Aminoisoquinoline derivatives as protein kinase inhibitors | |
| EP2922543A4 (en) | SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS | |
| EP3044225A4 (en) | Tricyclic gyrase inhibitors | |
| HK1217481A1 (zh) | 作為 抑制劑的氨基吡啶衍生的化合物 | |
| HK1213885A1 (zh) | 作為 抑制劑的咪唑並-三嗪衍生物 | |
| HK1220182A1 (zh) | 作為醛固酮合酶抑制劑的新的苯基-二氫吡啶衍生物 | |
| HK1211936A1 (en) | Dihydroquinoline-2-one derivatives for use as aldosterone synthase inhibitors -2- | |
| EP2968324A4 (en) | SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS | |
| HK1226072A1 (zh) | 作為bcl-3抑制劑的2-苯甲酰氨基苯甲酰胺衍生物 | |
| HK1217705A1 (zh) | 作爲醛固酮合酶抑制劑的苯基-二氫吡啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20240305 |